Shire [clinicaltrials_resource:7c5185501601fefe747cf96e7bec0fee]
Ann Barbier, MD [clinicaltrials_resource:0505a5ad65e856a5ea05bba16eb391fa]David Alexanderian, DO [clinicaltrials_resource:0b2a18dda8ebff4a1b8962ef58b457d3]Adina Tocoian, MD, PhD [clinicaltrials_resource:0ee4a5ff87bae37059ddadcafb3ef799]David Alexanderian, MD [clinicaltrials_resource:116693be2d09a1711f641467a3a8d1d9]Vipin Aggarwal, MD, MPH [clinicaltrials_resource:127d3529c369fee95594b8a91cfa0df3]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]David Alexanderian, DO [clinicaltrials_resource:1716f51900f29588dee35f7b8bedfe0c]Glen Frick, MD, PhD [clinicaltrials_resource:1a404c1ede71be15c5e42b5869d55ccd]Glen Frick, MD, PhD [clinicaltrials_resource:1ca190ab9e4e86be6e77910693610b81]Raymond Pratt, MD [clinicaltrials_resource:235a87163cf0ab3c38afb88be951b0a4]Glen Frick, MD, PhD [clinicaltrials_resource:2544dae1e8c5ce46784b9ce6d6936929]Dasotraline Medical Director, MD [clinicaltrials_resource:2611854ac19dc61cd9c528f8cc402f73]Gerald Tremblay [clinicaltrials_resource:28b0b09dac7bf51e3f86bd1a944f0832]Julio Casoy, MD [clinicaltrials_resource:2d2c1d35e3c8115e18499185ce3f8e8d]David Whiteman, MD, FAAP, FACMG [clinicaltrials_resource:3b4ce66f3d884fa8b3222f449c6f602a]Glen Frick, MD, PhD [clinicaltrials_resource:3e5e39a665856f4d3d82d90a832d751d]Anna Wijatyk, MD [clinicaltrials_resource:4037b0654585e4af390d70519e9460e0]Vipin Aggarwal, MD, MPH [clinicaltrials_resource:41104e59b25534ceabb05427d17c5793]David Alexanderian, DO [clinicaltrials_resource:482b9f9255cee862aa3cd2f4dc06a5a2]Ann Barbier, M.D. [clinicaltrials_resource:4d2b3f406c64c8171130625668404beb]Arian Pano, MD, MPH [clinicaltrials_resource:53ccfab19659f2c454089358ff562a4b]David Alexanderian, DO [clinicaltrials_resource:556798d0c2c854c2a123861e835653fc]Björn Mellgard, MD PhD [clinicaltrials_resource:5603d73795607d9d96c18d3cf1c7cb6f]Anna Wijatyk, MD [clinicaltrials_resource:562db3d0bbfab16ea08b2ca2d23e53c2]Anna Wijatyk, MD [clinicaltrials_resource:59379b77bbcc92e0bcecc6f16addb507]David Alexanderian, DO [clinicaltrials_resource:5cdabb56d79d8214abd2a5d7dce765b6]Irmgard Andresen, MD [clinicaltrials_resource:6421958f7d73ef4f77a47ddf162575fc]Irmgard Andersen, MD, FFPM [clinicaltrials_resource:6480c6e0a98255b7c703717f219ae74f]Vipin Aggarwal, MD, MPH [clinicaltrials_resource:6758461fcf36db0fb9cacf98aa45485c]David Alexanderian, DO [clinicaltrials_resource:6d022cf0e98e8cd592793eb210e5a92d]Jennifer Schranz, MD [clinicaltrials_resource:7082d833c73a599d2b3759b51229e6ba]Vipin Aggarwal, MD, MPH [clinicaltrials_resource:71abaaddff860c60b0460bde19bd6f15]Vipin Aggarwal, MD, MPH [clinicaltrials_resource:754d351e6da757f665ac56dd0ad5fac5]Patrick Martin, MD [clinicaltrials_resource:76674883ffd02db5453650aa9f75ac72]Anna Wijatyk, MD [clinicaltrials_resource:7996818a654c396a7929869e956b1b76]Bjorn Mellgard, M.D. [clinicaltrials_resource:81243c37105f7ca13245ededde5cba04]Björn Mellgard, MD [clinicaltrials_resource:897645b08e783d24d63ead0aa7008c94]Garrick Fiddler, MD [clinicaltrials_resource:9af10c3ca568c84c502a18c723c4e525]Patrick Martin [clinicaltrials_resource:9cca71fd97671ee8e54c09b859f9b955]Adina Tocoian, MD, PhD [clinicaltrials_resource:a22bdf4889070abfcd843df6330e4189]
affiliation [clinicaltrials_vocabulary:affiliation]
clinicaltrials:NCT00478647clinicaltrials:NCT00607386clinicaltrials:NCT00997204Firazyr® Patient Registry Protocol (Icatibant Outcome Survey - IOS) [clinicaltrials:NCT01034969]An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD) [clinicaltrials:NCT01093105]clinicaltrials:NCT01330381clinicaltrials:NCT01426763clinicaltrials:NCT01756157Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease [clinicaltrials:NCT01842841]Open-Label Extension Study Evaluating Safety and Efficacy of HGT-1110 in Patients With Metachromatic Leukodystrophy [clinicaltrials:NCT01887938]clinicaltrials:NCT01919801Natural History Study of Children With Metachromatic Leukodystrophy [clinicaltrials:NCT01963650]clinicaltrials:NCT02057692clinicaltrials:NCT02060526An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome [clinicaltrials:NCT02117713]
collaborator [clinicaltrials_vocabulary:collaborator]
clinicaltrials:NCT00012259A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension [clinicaltrials:NCT00046163]A Study for Patients With Neurogenic Orthostatic Hypotension [clinicaltrials:NCT00046475]clinicaltrials:NCT00069641clinicaltrials:NCT00084084clinicaltrials:NCT00097695A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol. [clinicaltrials:NCT00150540]Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood [clinicaltrials:NCT00150566]Efficacy and Safety of SPD465 in Adults With ADHD [clinicaltrials:NCT00150579]Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17 [clinicaltrials:NCT00150592]Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17 [clinicaltrials:NCT00150618]clinicaltrials:NCT00151892Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease [clinicaltrials:NCT00151918]Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis [clinicaltrials:NCT00151931]Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis. [clinicaltrials:NCT00151944]Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) [clinicaltrials:NCT00151996]Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17 [clinicaltrials:NCT00152009]Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD. [clinicaltrials:NCT00152022]Safety of SPD465 in Treating Adults With ADHD. [clinicaltrials:NCT00152035]Evaluation of Eflornithine on Facial and Forearm Skin [clinicaltrials:NCT00152048]Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease [clinicaltrials:NCT00160121]Safety and Efficacy of SPD465 in Adults With ADHD [clinicaltrials:NCT00202605]A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients [clinicaltrials:NCT00202644]Maribavir for Prevention of CMV After Stem Cell Transplants [clinicaltrials:NCT00223925]Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease [clinicaltrials:NCT00234702]clinicaltrials:NCT00289211clinicaltrials:NCT00367835clinicaltrials:NCT00411645clinicaltrials:NCT00413634Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) [clinicaltrials:NCT00418561]clinicaltrials:NCT00430625Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects [clinicaltrials:NCT00432510]clinicaltrials:NCT00438815clinicaltrials:NCT00441545clinicaltrials:NCT00446849clinicaltrials:NCT00450333Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 [clinicaltrials:NCT00452478]A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators [clinicaltrials:NCT00458445]clinicaltrials:NCT00462709clinicaltrials:NCT00478647
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
organization [clinicaltrials_vocabulary:organization]
clinicaltrials:NCT00012259A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension [clinicaltrials:NCT00046163]A Study for Patients With Neurogenic Orthostatic Hypotension [clinicaltrials:NCT00046475]clinicaltrials:NCT00069641clinicaltrials:NCT00084084clinicaltrials:NCT00097695A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol. [clinicaltrials:NCT00150540]Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood [clinicaltrials:NCT00150566]Efficacy and Safety of SPD465 in Adults With ADHD [clinicaltrials:NCT00150579]Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17 [clinicaltrials:NCT00150592]Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17 [clinicaltrials:NCT00150618]clinicaltrials:NCT00151892Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease [clinicaltrials:NCT00151918]Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis [clinicaltrials:NCT00151931]Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis. [clinicaltrials:NCT00151944]Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD) [clinicaltrials:NCT00151996]Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17 [clinicaltrials:NCT00152009]Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD. [clinicaltrials:NCT00152022]Safety of SPD465 in Treating Adults With ADHD. [clinicaltrials:NCT00152035]Evaluation of Eflornithine on Facial and Forearm Skin [clinicaltrials:NCT00152048]Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease [clinicaltrials:NCT00160121]Safety and Efficacy of SPD465 in Adults With ADHD [clinicaltrials:NCT00202605]A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients [clinicaltrials:NCT00202644]Maribavir for Prevention of CMV After Stem Cell Transplants [clinicaltrials:NCT00223925]Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease [clinicaltrials:NCT00234702]clinicaltrials:NCT00289211clinicaltrials:NCT00367835clinicaltrials:NCT00411645clinicaltrials:NCT00413634Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD) [clinicaltrials:NCT00418561]clinicaltrials:NCT00430625Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects [clinicaltrials:NCT00432510]clinicaltrials:NCT00438815clinicaltrials:NCT00441545clinicaltrials:NCT00446849clinicaltrials:NCT00450333Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 [clinicaltrials:NCT00452478]A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators [clinicaltrials:NCT00458445]clinicaltrials:NCT00462709clinicaltrials:NCT00478647
source [clinicaltrials_vocabulary:source]
Shire [clinicaltrials_resource:7c5185501601fefe747cf96e7bec0fee]
Bio2RDF identifier
7c5185501601fefe747cf96e7bec0fee
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:7c5185501601fefe747cf96e7bec0fee
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:7c5185501601fefe747cf96e7bec0fee
title
Shire
@en
type
label
Shire [clinicaltrials_resource:7c5185501601fefe747cf96e7bec0fee]
@en